"The decline comes as a growing number of Americans turn to GLP-1 drugs to lose weight. Gallup found that the use of these drugs specifically to lose weight (they're also used to treat diabetes) has more than doubled from February 2024, when it was 5.8%, to 12.4% currently: More women (15.2%) are taking the drugs than men (9.7%), which correlates with a slightly larger decline in obesity rates among women."
"Eli Lilly reported stellar third-quarter earnings yesterday and raised this year's revenue estimates from $60 billion-$62 billion to $63 billion-$63.5 billion, crediting the growing adoption of its weight loss drugs Zepound and Mounjaro. The company also announced a direct-to-consumer partnership with Walmart, offering customers single-dose vials of Zepbound for under $500 in its pharmacies. Meanwhile, other pharma companies are desperately trying to claw back market share of obesity drugs, which is expected to reach $150 billion by 2030."
U.S. adult obesity fell to 37% this year from a nearly 40% peak three years earlier. Use of GLP-1 drugs specifically for weight loss rose from 5.8% in February 2024 to 12.4% currently, with higher uptake among women (15.2%) than men (9.7%) and the highest use (17%) among adults aged 50–64. Pharmaceutical companies are profiting as adoption grows: Eli Lilly raised revenue forecasts to $63–$63.5 billion and partnered with Walmart to sell single-dose Zepbound vials for under $500. Competitors are vying for market share through bids and acquisitions targeting new GLP-1 developments.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]